Perpetual LTD Vertex Pharmaceuticals Inc Transaction History

Perpetual LTD

$9.23 Trillion
Q3 2024

A detailed history of Perpetual LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Perpetual LTD holds 167,221 shares of VRTX stock, worth $78.3 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares

167,221

Previous 170,175 1.74%

Holding current value

$78.3 Million

Previous $79.8 Billion 2.5%

% of portfolio

0.84%

Previous 0.87%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 09, 2024	SELL	$460.0 - $505.78 $1.36 Million - $1.49 Million	-2,954 Reduced 1.74%	167,221 $77.8 Billion
Q2 2024 Jul 30, 2024	SELL	$392.81 - $485.53 $10.7 Million - $13.2 Million	-27,176 Reduced 13.77%	170,175 $79.8 Billion
Q1 2024 Apr 09, 2024	SELL	$407.69 - $446.08 $4.22 Million - $4.62 Million	-10,352 Reduced 4.98%	197,351 $82.5 Billion
Q4 2023 Feb 15, 2024	SELL	$343.0 - $410.68 $20.5 Million - $24.6 Million	-59,803 Reduced 22.36%	207,703 $84.5 Billion
Q3 2023 Oct 10, 2023	SELL	$338.18 - $362.46 $1.01 Million - $1.08 Million	-2,976 Reduced 1.1%	267,506 $93 Billion
Q2 2023 Jul 13, 2023	SELL	$314.42 - $351.91 $10.3 Million - $11.5 Million	-32,747 Reduced 10.8%	270,482 $95.2 Billion
Q1 2023 May 08, 2023	BUY	$283.23 - $323.1 $78.8 Million - $89.9 Million	278,379 Added 1120.24%	303,229 $95.5 Billion
Q3 2020 Dec 08, 2020	SELL	$255.65 - $303.1 $483,178 - $572,859	-1,890 Reduced 7.07%	24,850 $6.76 Million
Q2 2020 Nov 18, 2020	SELL	$225.48 - $295.8 $2.29 Million - $3.01 Million	-10,170 Reduced 27.55%	26,740 $16.4 Million
Q1 2020 Nov 18, 2020	BUY	$199.77 - $247.81 $7.37 Million - $9.15 Million	36,910 New	36,910 $23.4 Million

Others Institutions Holding VRTX

# of Institutions

1,725

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perpetual LTD, based on Form 13F filings with the SEC.

News

Stay updated on Perpetual LTD with notifications on news.

Account